By Ian Walker

 

LONDON--Pharmaceutical giant AstraZeneca PLC (AZN.LN) said Tuesday the U.S. Food and Drug Administration has approved once-daily Qtern for the treatment of type-2 diabetes.

The new medicine is indicated as an addition to diet and exercise to improve blood sugar level control in adults with type-2 diabetes who have inadequate control with dapagliflozin, or who are already treated with dapagliflozin and saxagliptin, Astra said.

 

-Write to Ian Walker at ian.walker@wsj.com; @IanWalk40289749

 

(END) Dow Jones Newswires

February 28, 2017 02:34 ET (07:34 GMT)

Copyright (c) 2017 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Astrazeneca Charts.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Astrazeneca Charts.